206 related articles for article (PubMed ID: 12940460)
1. Human pituitary adenomas infrequently contain inactivation of retinoblastoma 1 gene and activation of cyclin dependent kinase 4 gene.
Honda S; Tanaka-Kosugi C; Yamada S; Sano T; Matsumoto T; Itakura M; Yoshimoto K
Endocr J; 2003 Jun; 50(3):309-18. PubMed ID: 12940460
[TBL] [Abstract][Full Text] [Related]
2. The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas.
Ogino A; Yoshino A; Katayama Y; Watanabe T; Ota T; Komine C; Yokoyama T; Fukushima T
J Neuropathol Exp Neurol; 2005 May; 64(5):398-403. PubMed ID: 15892297
[TBL] [Abstract][Full Text] [Related]
3. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island.
Simpson DJ; Hibberts NA; McNicol AM; Clayton RN; Farrell WE
Cancer Res; 2000 Mar; 60(5):1211-6. PubMed ID: 10728677
[TBL] [Abstract][Full Text] [Related]
4. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
Kirsch M; Mörz M; Pinzer T; Schackert HK; Schackert G
Genes Chromosomes Cancer; 2009 Feb; 48(2):143-54. PubMed ID: 18973139
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of G(1)/S regulators is a frequent event in sporadic pituitary adenomas.
Simpson DJ; Frost SJ; Bicknell JE; Broome JC; McNicol AM; Clayton RN; Farrell WE
Carcinogenesis; 2001 Aug; 22(8):1149-54. PubMed ID: 11470742
[TBL] [Abstract][Full Text] [Related]
6. Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours.
Vax VV; Bibi R; Diaz-Cano S; Gueorguiev M; Kola B; Borboli N; Bressac-de Paillerets B; Walker GJ; Dedov II; Grossman AB; Korbonits M
J Endocrinol; 2003 Aug; 178(2):301-10. PubMed ID: 12904177
[TBL] [Abstract][Full Text] [Related]
7. Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus.
Zhu J; Leon SP; Beggs AH; Busque L; Gilliland DG; Black PM
J Clin Endocrinol Metab; 1994 Apr; 78(4):922-7. PubMed ID: 8157722
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of molecular genetic changes in sporadic invasive pituitary adenomas.
Nam DH; Song SY; Park K; Kim MH; Suh YL; Lee JI; Kim JS; Hong SC; Shin HJ; Park K; Eoh W; Kim JH
Exp Mol Med; 2001 Sep; 33(3):111-6. PubMed ID: 11642545
[TBL] [Abstract][Full Text] [Related]
9. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A.
Møller MB; Kania PW; Ino Y; Gerdes AM; Nielsen O; Louis DN; Skjødt K; Pedersen NT
Leukemia; 2000 May; 14(5):898-904. PubMed ID: 10803523
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas.
Yoshino A; Katayama Y; Ogino A; Watanabe T; Yachi K; Ohta T; Komine C; Yokoyama T; Fukushima T
J Neurooncol; 2007 Jun; 83(2):153-62. PubMed ID: 17216555
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity and mutations are the major mechanisms of RB1 gene inactivation in Chinese with sporadic retinoblastoma.
Choy KW; Pang CP; Yu CB; Wong HL; Ng JS; Fan DS; Lo KW; Chai JT; Wang J; Fu W; Lam DS
Hum Mutat; 2002 Nov; 20(5):408. PubMed ID: 12402348
[TBL] [Abstract][Full Text] [Related]
12. Analysis of cell cycle regulators: p16INK4A, pRb, and CDK4 in low- and high-grade meningiomas.
Tse JY; Ng HK; Lo KW; Chong EY; Lam PY; Ng EK; Poon WS; Huang DP
Hum Pathol; 1998 Nov; 29(11):1200-7. PubMed ID: 9824096
[TBL] [Abstract][Full Text] [Related]
13. Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer.
Bièche I; Lidereau R
Mol Carcinog; 2000 Nov; 29(3):151-8. PubMed ID: 11108660
[TBL] [Abstract][Full Text] [Related]
14. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer.
Cetani F; Pardi E; Viacava P; Pollina GD; Fanelli G; Picone A; Borsari S; Gazzerro E; Miccoli P; Berti P; Pinchera A; Marcocci C
Clin Endocrinol (Oxf); 2004 Jan; 60(1):99-106. PubMed ID: 14678295
[TBL] [Abstract][Full Text] [Related]
15. GH-secreting pituitary adenomas infrequently contain inactivating mutations of PRKAR1A and LOH of 17q23-24.
Yamasaki H; Mizusawa N; Nagahiro S; Yamada S; Sano T; Itakura M; Yoshimoto K
Clin Endocrinol (Oxf); 2003 Apr; 58(4):464-70. PubMed ID: 12641630
[TBL] [Abstract][Full Text] [Related]
16. Expression of the cell-cycle regulatory proteins (pRb, cyclin D1, p16INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features.
Semczuk A; Miturski R; Skomra D; Jakowicki JA
Arch Gynecol Obstet; 2004 Jan; 269(2):104-10. PubMed ID: 14648178
[TBL] [Abstract][Full Text] [Related]
17. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas.
Burns KL; Ueki K; Jhung SL; Koh J; Louis DN
J Neuropathol Exp Neurol; 1998 Feb; 57(2):122-30. PubMed ID: 9600204
[TBL] [Abstract][Full Text] [Related]
18. Mutation analysis of the pRb pathway in 2',3'-dideoxycytidine- and 1, 3-butadiene-induced mouse lymphomas.
Zhuang SM; Wiseman RW; Söderkvist P
Cancer Lett; 2000 May; 152(2):129-34. PubMed ID: 10773403
[TBL] [Abstract][Full Text] [Related]
19. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
Nielsen GP; Burns KL; Rosenberg AE; Louis DN
Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
[TBL] [Abstract][Full Text] [Related]
20. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
